Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with PAD：Phase II

Inclusion Criteria: * 1\. History of PAD, or a history of intermittent claudication with an ankle/brachial blood pressure ratio \< 0.9, or angiography-confirmed significant peripheral arterial stenosis (≥50%). 2\. Underwent endovascular treatment for aortoiliac, femoral, popliteal, or infrapopliteal arteries. 3\. No restrictions on endovascular treatment methods, including all internationally recognized devices and techniques used in real-world practice. 4\. Agreed and signed the informed consent form. Exclusion Criteria: * 1\. \*\*Patients with a history of stroke within the past month\*\* or a history of hemorrhagic or lacunar stroke. 2\. Patients with a known ejection fraction \< 30% or severe heart failure with Class III/IV symptoms. 3\. Patients with non-cardiovascular diseases associated with poor prognosis(e.g., metastatic cancer) or interventions that increase the risk of adverse events in the study. 4\. Patients with a history of allergies or known contraindications to drugs such as rivaroxaban or aspirin. 5\. Patients with any known liver disease associated with coagulation disorders. 6. Pregnant or breastfeeding women, or women of childbearing potential who are sexually active and not using effective contraception. 7\. Patients with known contraindications to any study-related procedures.